Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 5/20 | 0.48 |
| ▸ | CTSS | P25774 | 3/20 | 0.48 |
| ▸ | CTSK | P43235 | 4/20 | 0.45 |
| ▸ | CTSB | P07858 | 2/20 | 0.45 |
| ▸ | CCR1 | P32246 | 2/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.44 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | PREP | P48147 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19333018 | 0.82 | CAPN1 (0.41) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL15937145 | 0.82 | CTSL (0.47) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL19333020 | 0.81 | CTSL (0.41) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL17356215 | 0.81 | CTSK (0.43) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL17352423 | 0.81 | CTSK (0.43) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL15924794 | 0.81 | HTR2C (0.47) | — | |
| SCHEMBL15937156 | 0.77 | CAPN1 (0.39) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL17356219 | 0.76 | CAPN1 (0.47) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL17281441 | 0.75 | CCR1 (0.50) | CTSLCTSSCTSKCTSBCCR1 | |
| SCHEMBL20329133 | 0.75 | CAPN1 (0.40) | CTSLCTSSCTSKCTSBCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2018-06-28 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758525-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSL 3751/4885CTSS 4304/4885CTSK 4114/4885 |
| US-20180179217-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSL 3751/4885CTSS 4304/4885CTSK 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.